Intelligence · Patents
Patents expiring in 2037
Annual patent cliff calendar for 2037 — US pharmaceutical patents by expiration date.
- Patents
- 1,615
Quick answer
1,615 indexed pharmaceutical patents have expiration dates in 2037. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 9820952
Solid solution compositions and use in chronic inflammation
granted -
US 9820970
Method and agent for the treatment and prophylaxis of diseases caused by (+)RNA-containing viruses
granted -
US 9821054
Method of vaccination comprising a histone deacetylase inhibitor
granted -
US 9822117
Pyridoindolobenz[b,d]azepine derivatives and uses thereof
granted -
PT 2114927
PROCESS FOR THE PREPARATION OF (R)-5-(2-AMINOETHYL)-1-(6,8-DIFLUOROCHROMAN-3-YL)-1,3-DIHYDROIMIDAZOLE-2-THIONE
granted -
US 9828452
Process for the synthesis of poly (vinyl alcohol) and/or poly (vinyl acetate) with spherical morphology and shell-and-nucleus structure and its use in vascular embolization
granted -
US 9828370
Compositions and methods for inhibiting kinases
granted -
US 9828373
2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
granted -
US 9828397
Prodrugs of pyridone amides useful as modulators of sodium channels
granted -
US 9828357
Cyclic compounds
granted -
US 9828435
Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequency
granted -
US 9828426
Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
granted -
US 9828410
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted -
US 9828367
Neprilysin inhibitors
granted -
US 9827295
Methods to treat mucopolysaccharide type I or deficiency in alpha-L-iduronidase using a recombinant adeno-associated virus encoding alpha-L-iduronidase
granted -
US 9828352
Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR)
granted -
US 9827223
Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist
granted -
US 9827215
Solid solution compositions and use in chronic inflammation
granted -
US 9827233
Methods of treating behavioral syndromes using pipradrol
granted -
US 9827239
Oligomer-opioid agonist conjugates
granted -
US 9827228
Opioid receptor modulators and use thereof
granted -
US 9827202
Hot-melt extrusion of modified release multi-particulates
granted -
US 9827350
Solubilization of antigen components for removal from tissues
granted -
US 9827326
Polymer-sunitinib conjugates
granted -
US 9827310
Anti-ErbB3 antibodies and uses thereof
granted -
US 9827327
Methods and compositions related to adenoassociated virus-phage particles
granted -
US 9827255
Fumagillol derivatives
granted -
US 9827353
Cross-linked fatty acid-based biomaterials
granted -
US 9827352
Cross-linked fatty acid-based biomaterials
granted -
US 9827394
Dispersion anaesthetic device
granted -
US 9827272
Growth factor sequestering and presenting hydrogels
granted -
US 9827290
Compositions and methods relating to induction of intestinal stem cell homeogenesis and/or regeneration
granted -
US 9827268
Curable calcium phosphate composition for biological hard tissue repair, bone repair material, and various dental materials
granted -
US 9827263
2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
granted -
US 9827241
Injectable flowable composition comprising buprenorphine
granted -
US 9829495
Method for differentially diagnosing ACTH-dependent Cushing's syndrome
granted -
US 9828634
Markers for differentiation of stem cells into differentiated cell populations
granted -
US 9828465
N-maleimidyl polymer derivatives
granted -
US 9828432
Cancer treatment and monitoring methods using OX40 agonists
granted -
WO 2017203057
PROTÉINES IMMUNOGÈNES ET FRAGMENTS DE CELLES-CI À PARTIR D'ACARIENS ALLERGÈNES
granted -
US 2017340593
MEDICAMENTS FOR SLOWING PARKINSON'S DISEASE
granted -
US 9833437
Small molecule inhibitor of MYD88 for therapeutic treatment against alphavirus and staphylococcal enterotoxin infections and toxin exposure
granted -
US 9834757
Hand, foot, and mouth vaccines and methods of manufacture and use thereof
granted -
US 9834770
Single stranded DNA aptamers binding NF-kB/RelA
granted -
US 9834608
Binding-triggered transcriptional switches and methods of use thereof
granted -
US 9834588
Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
granted -
US 9834513
Benzylamine derivatives
granted -
US 9834587
Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
granted
Frequently asked questions
How many pharma patents expire in 2037?
1,615 published patents in our USPTO index have expiration dates falling in calendar year 2037.